Lv64
1630 积分 2022-06-08 加入
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
1天前
待确认
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
1天前
待确认
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
1天前
待确认
Cutaneous adverse events caused by immune checkpoint inhibitors
9天前
已完结
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects
25天前
已完结
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors
25天前
已完结
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy
25天前
已完结
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
25天前
已完结
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
26天前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
1个月前
已完结
皖公网安备34019202002308
